Robert Hewgley, PA
Physician Assistant · Wilmington, NCNPI 1912522996
Payments from drug & device makers
Across 191 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$558
- Novo Nordisk$547
- AstraZeneca$503
- Amgen$303
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$247
- Teva Pharmaceuticals USA, Inc.$213
- plus $2K from 31 others
What the payments were for
- Food & beverage$3,85199%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 44 | $558 |
| Novo Nordisk | 24 | $547 |
| AstraZeneca | 15 | $503 |
| Amgen(2 entities) | 8 | $303 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $247 |
| Teva Pharmaceuticals USA, Inc. | 10 | $213 |
| Bausch Health US, LLC | 8 | $164 |
| Otsuka America Pharmaceutical, Inc. | 3 | $146 |
| Axsome Therapeutics, Inc. | 5 | $115 |
| Merck | 7 | $110 |
| Alkermes, Inc. | 4 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $81 |
| Vanda Pharmaceuticals Inc. | 5 | $71 |
| Lilly USA, LLC | 3 | $66 |
| GSK | 4 | $62 |
| Astellas Pharma US Inc | 3 | $59 |
| Idorsia Pharmaceuticals US Inc | 4 | $55 |
| Pfizer | 3 | $54 |
| Boehringer Ingelheim | 3 | $50 |
| Abbott | 2 | $36 |
| Corcept Therapeutics | 2 | $32 |
| Almatica Pharma LLC | 2 | $31 |
| Eisai Inc. | 2 | $29 |
| Mylan Specialty L.p. | 1 | $29 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Nestle Healthcare Nutrition Inc. | 1 | $27 |
| Ironwood Pharmaceuticals, Inc | 2 | $26 |
| Viiv Healthcare Company | 1 | $21 |
| Johnson & Johnson | 1 | $21 |
| Indivior Inc. | 1 | $20 |
| Exact Sciences | 1 | $20 |
| Novartis | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,897 in reported general payments places this provider in the 90th percentile of 7,441 physician assistant providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 64 | $74,954 |
| VraylarCariprazine Hcl | 23 | $43,439 |
| Abilify MaintenaAripiprazole | 15 | $39,985 |
| MounjaroTirzepatide | 30 | $39,164 |
| FarxigaDapagliflozin Propanediol | 34 | $37,708 |
| JardianceEmpagliflozin | 32 | $34,966 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $32,747 |
| RybelsusSemaglutide | 19 | $20,493 |
| LinzessLinaclotide | 21 | $16,835 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 23 | $15,621 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $12,750 |
| SynjardyEmpagliflozin/Metformin Hcl | 18 | $11,884 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $11,461 |
| TrintellixVortioxetine Hydrobromide | 13 | $11,254 |
| VascepaIcosapent Ethyl | 19 | $9,301 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $547 | $95,44783 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat, Synjardy | $50 | $75,22199 claims |
| AbbVieVraylar, Linzess, Synthroid | $558 | $61,45157 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $503 | $55,10381 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $146 | $39,98515 claims |
| Lilly USA, LLCMounjaro | $66 | $39,16430 claims |
| GSKTrelegy Ellipta | $62 | $32,74749 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $81 | $15,71025 claims |
| MerckBelsomra | $110 | $5,83313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,441 physician assistant providers in North Carolina.
Other physician assistant in Wilmington
- Leighton MorganWilmington$21K
- Jo HughesGreensboro$814K
- Rachel HolzhauerCharlotte$739K
- Amber BlairCharlotte$551K
- Benjamin EpsteinDavidson$447K
- Rebecca KrausDavidson$425K
- Brooke JonesGoldsboro$259K
- Philip ReasbeckWilson$180K
- Katherine SchultzHuntersville$164K
- Kristin CabedaCharlotte$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.